Results 161 to 170 of about 44,865 (239)

<i>BRAF V600E</i> liquid biopsy-based detection in precision oncology. [PDF]

Adv Lab Med
Mendeluk GR, Alonso VA.
europepmc   +1 more source

Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis. [PDF]

Curr Oncol
Dankner M, Dubé LR, Sorin M, Stein AJB, Nowakowski A, Park CL, Magrill J, Lazaratos AM, Romero JM, Batist G, Kavan P, Rose AAN, Ma K.   +12 more
europepmc   +1 more source

Association of Gene Expression Alterations with Aggressive Features in Papillary Thyroid Carcinomas Harboring Low Allele Frequency BRAF V600E Mutations. [PDF]

J Otolaryngol Head Neck Surg
Katz A, Lefebvre C, Bandargal S, Forest VI, Pusztaszeri MP, Payne RJ.   +5 more
europepmc   +1 more source

Prognostic analysis and expression patterns of programmed cell death ligand 1 and BRAF V600E in esophageal neuroendocrine carcinoma. [PDF]

Oncol Lett
Zhang C, Zheng L, Xu B, Shi G, Fu M.
europepmc   +1 more source

Ophthalmic Toxicities in BEACON Triplet Therapy for BRAF V600E-Mutant Colorectal Cancer: A Case Series. [PDF]

J Anus Rectum Colon
Nakamura H, Suzumura K, Oiwa K, Tsuchiya T, Nishimae K, Tanaka M, Terasaki M, Okamoto Y.   +7 more
europepmc   +1 more source

Targeted therapy in melanoma [PDF]

, 2009
Tawbi,
core   +1 more source

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. [PDF]

Future Oncol
Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ.   +20 more
europepmc   +1 more source

A case report of neoadjuvant targeted therapy in stage IIIA non-small cell lung cancer with <i>BRAF V600E</i> mutation. [PDF]

Front Med (Lausanne)
Peng W, Qu S, Cai L, Yang R, Dong M, Li X, Ran F, Luo C.   +7 more
europepmc   +1 more source

Relationship between the BRAF-V600E variant allele frequency and clinicopathological characteristics of papillary thyroid carcinoma and its clinical application. [PDF]

Discov Oncol
Wang S, Ding Y, Geng X, Wu W, Ju F, Yan X, Li Y, Lyu G.   +7 more
europepmc   +1 more source

BRAF inhibitor or BRAF/MEK inhibitor treatment for patients with metastatic BRAF V600E mutated differentiated thyroid cancer. [PDF]

Arch Endocrinol Metab
Finkel I, Korzets Y, Moore A, Coreanu T, Popovtzer A, Shoffel-Havakuk H, Bachar G, Mansour J, Weiss C, Robenshtok E.   +9 more
europepmc   +1 more source